Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 75 of 341 entries
View as:
Phase: N/A
Priority: Normal
Start: 05/31/14
End: 12/31/14
Due: 12/31/15
Phase: N/A
Priority: Normal
Start: 01/20/25
End: 06/30/26
Due: 06/30/27
Phase: N/A
Priority: Normal
Start: 12/06/17
End: 11/29/18
Due: 11/29/19
Phase: N/A
Priority: Normal
Start: 07/21/21
End: 06/01/26
Due: 06/01/27
Phase: N/A
Priority: Normal
Start: 01/01/20
End: 12/30/22
Due: 12/30/23
Phase: N/A
Priority: Normal
Start: 01/05/18
End: 03/02/19
Due: 03/02/20
Phase: N/A
Priority: Normal
Start: 07/05/24
End: 05/31/29
Due: 05/31/30
Phase: N/A
Priority: Normal
Start: 11/15/24
End: 10/31/29
Due: 10/31/30
Phase: N/A
Priority: Normal
Start: 08/31/14
End: 04/30/16
Due: 04/30/17
Phase: N/A
Priority: Normal
Start: 03/31/21
End: 09/30/23
Due: 09/30/24
Phase: N/A
Priority: Normal
Start: 08/09/24
End: 08/01/26
Due: 08/01/27
Phase: N/A
Priority: Normal
Start: 07/22/24
End: 06/22/29
Due: 06/22/30
Apatinib Combine With Platinum-Based Doublet Chemotherapy for First-line Treatment of Advanced NSCLC
Phase: N/A
Priority: Normal
Start: 06/27/17
End: 08/01/20
Due: 08/01/21
Phase: N/A
Priority: Normal
Start: 12/10/20
End: 12/30/24
Due: 12/30/25
Phase: N/A
Priority: Normal
Start: 11/30/23
End: 11/30/26
Due: 11/30/27
Phase: N/A
Priority: Normal
Start: 08/01/22
End: 11/30/22
Due: 11/30/23
Phase: N/A
Priority: Normal
Start: 02/27/20
End: 07/27/24
Due: 07/27/25
Phase: N/A
Priority: Normal
Start: 12/01/15
End: 01/15/17
Due: 01/15/18
Phase: N/A
Priority: Normal
Start: 05/31/16
End: 05/31/17
Due: 05/31/18
Phase: N/A
Priority: Normal
Start: 11/20/19
End: 11/18/21
Due: 11/18/22
Phase: N/A
Priority: Normal
Start: 01/31/24
End: 11/13/29
Due: 11/13/30
Phase: N/A
Priority: Normal
Start: 05/31/15
End: 12/31/18
Due: 12/31/19
Phase: N/A
Priority: Normal
Start: 06/01/20
End: 05/31/25
Due: 05/31/26
Phase: N/A
Priority: Normal
Start: 02/15/23
End: 01/01/25
Due: 01/01/26
Phase: N/A
Priority: Normal
Start: 01/01/07
End: 12/31/18
Due: 12/31/19